Atopic Dermatitis

RESEARCH STUDY FOR ATOPIC DERMATITIS (25-41 WEEKS)

Adults with a clinical diagnosis of atopic dermatitis (AD) are needed for this clinical research trial. Eligible participants must have experienced symptoms for at least 3 years. Participants also must either have a history of inadequate response to previous systemic treatments for AD, or that other systemic treatments have been medically inadvisable. All participants will receive investigational oral or subcutaneous injection (SC) treatments (active study drugs) during the treatment period. You will not be charged for study medication and study-related assessments.

Reimbursement for study-related expenses (such as travel expense) will be provided. Study participation will last between 25-41 weeks and involve about 10 visits to the study centre.

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis – Full Text View – ClinicalTrials.gov

 

 

RESEARCH STUDY FOR ATOPIC DERMATITIS (32 WEEKS)

Adults from 18 to less than 65 years of age having chronic atopic dermatitis (AD) with an onset of symptoms at least 3 years prior to Baseline, may qualify to receive one of two doses of investigational medication (active study drug).

To be eligible, participants must have moderate to severe AD with involvement of 10% or more body surface area (BSA). Qualified participants must be candidates for systemic treatment defined as prior use of systemic treatment for AD, or previous inadequate response to topical corticosteroids (TCS), topical calcineurin inhibitors (TCI) or PDE-4 inhibitors, or for whom topical treatments are otherwise medically inadvisable.

Eligible participants will have regular visits with an experienced research team. Qualified participants will not be charged for participating, and participants will be reimbursed for some study-related expenses. Individuals will be asked to visit the study centre about 7 times over a period of about 32 weeks.

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis – Full Text View – ClinicalTrials.gov

RESEARCH STUDY FOR ATOPIC DERMATITIS (40 WEEKS)

Adults aged 18 and over with a diagnosis of atopic dermatitis (AD) that has been present for at least 6 months are needed for this research trial. Participants will receive an investigational medication (active study drug) or placebo via injection.

To be eligible, participants must have moderate to severe eczema with involvement of 10% or more body surface area (BSA), and a history of inadequate response to topical corticosteroids (TCS) of medium to higher potency within 6 months, or for whom topical treatments are otherwise medically inadvisable.

Eligible participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Individuals will be asked to visit the study centre about 11 times over a period of about 40 weeks.

 

 

 

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Jackie Nguyen
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallett: 9623 9406
e: [email protected]

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Jackie Nguyen
t: 9623 9464
e: [email protected]

Study Coordinator
Bailey Elward: 9623 9425
e: [email protected]

For more information, please contact:

Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Jackie Nguyen
t: 9623 9464
e: [email protected]

Study Coordinator
Tracy Mallett: 9623 9406
e: [email protected]

Scroll to Top